MiR-19a injected into the post-MI myocardium reduces damage to the heart by inhibiting target proteins, like phosphatase and tensin homolog (PTEN), and activating the Akt and ERK pathways [43]. The gene discussed is PTEN; the disease is myocardial infarction.